| HOME >> BIOLOGY >> TECHNOLOGY |
First Quarter Target Agreed
GENEVA, Switzerland, February 11 /PRNewswire-FirstCall/ -- Acrongenomics, Inc. (OTCBB:AGNM), the Geneva based technology development group have agreed with Molecular Vision and The Imperial Venture Fund a time line for the full acquisition of Molecular Vision. Following the initial acquisition of 10.9% of the shares of Molecular Vision announced earlier this month, it has now been agreed by all parties that the full acquisition of Molecular Vision will be completed before the end of Q1 2008.
Acrongenomics is an established company that identifies and then
invests in groundbreaking technologies. In May 2006, the Company first
identified the combination of microfluidics and light responsive polymers
being developed by Molecular Vision as having the potential of completely
revolutionising the Point of Care (PoC) diagnostics market. In a simple to
use compact hand held device the analytical capabilities of a number of
standard pieces of laboratory equipment can be duplicated. This means that
a very wide range of diagnostic tests based on the same procedures that are
used in the laboratory, will now be available to be undertaken in a
physicians office, or even in the field if you were, for example, trying to
identify an outbreak of infectious disease in farm animals. This wide
utility was identified by Acrongenomics and resulted in them investing US $
4.6million in Molecular Vision in order to build a prototype of the hand
held device and undertake trials comparing the results obtained with the
device with those obtained from standard pieces of equipment routinely used
in Pathology Laboratories. The results of comparative trial measuring
creatinine in urine will be presented comparing the Molecular Vision device
with the Siemens DCA 2000. These results have shown good correlation. A
further comparative trial measuring vitamin C is underway and various blood
based tests are being planned. Once these comp
'/>"/>
| SOURCE Acrongenomics, Inc. Copyright©2008 PR Newswire. All rights reserved |